M A Cawthorne
Publications
I.
Peer Reviewed Publications
1.
M.A. Cawthorne (1966). Separation of some oxine derivatives on thin layers
impregnated with ferric chloride. J. Chromatog., 25, 164-166.
2.
M.A. Cawthorne, A.T. Diplock, I.R. Muthy, J. Bunyan, Elspeth A. Murrell and J. Green
(1967). Vitamin E and stress 5. The effect of high and low oxygen tension on the
metabolism of [14C]D-tocopherol in the vitamin E-deficient rat. Br. J. Nutr., 21,
671-679.
3.
A.T. Diplock, J. Green, J. Bunyan, M.A. Cawthorne and Jean Dawson (1967).
Vitamin E and stress 6. Iron overloading and the metabolism of D-tocopherol in the
rat. Br. J. Nutr,. 21, 725-730.
4.
J. Green, I.R. Murphy, A.T. Diplock, J. Bunyan, M.A. Cawthorne, and Elspeth A.
Murrell. Vitamin E and stress 7. The interrelationships between polyunsaturated fatty
acid stress, vitamin A and vitamin E in the rat and the chick. Br. J. Nutr., 21, 845-863.
5.
J. Bunyan, A.T. Diplock, M.A. Cawthorne and J. Green (1968). Vitamin E and stress
8. Nutritional effects of dietary stress with silver in vitamin E-deficient chicks and rats.
Br. J. Nutr., 22, 165-181.
6.
L.R. Jeffries, M.A. Cawthorne, Margaret Harris, A.T. Diplock, J. Green and S.A. Price
(1967). Distribution of menaquinones in aerobic micrococcaceae. Nature, 215,
257-259.
7.
J. Bunyan, J. Green, Elspeth A. Murrell, A.T. Diplock and M.A. Cawthorne (1968). On
the postulated peroxidation of unsaturated lipids in the tissues of vitamin E-deficient
rats. Br. J. Nutr., 22, 97-109.
8.
M.A. Cawthorne, J. Bunyan, A.T. Diplock, Elspeth A. Murrell and J. Green (1968). On
the relationship between vitamin A and vitamin E in the rat. Br. J. Nutr., 22, 133-143.
9.
A.T. Diplock, M.A. Cawthorne, Elspeth A. Murrell, J. Green and J. Bunyan (1968).
Measurements of lipid peroxidation and tocopherol destruction in vitro and in vivo and
their significance in connection with the biological function of vitamin E. Br. J. Nutr.,
22, 465-471.
10.
J. Bunyan, J. Green and M.A. Cawthorne (1968). Effects of protein and vitamin E on
haemoglobin formation in rats. Br. J. Nutr., 22, 751-755.
11.
L.R. Jeffries, M.A. Cawthorne, Margaret Harris, Barbara Cook and A.T. Diplock
(1969). Menaquinone determination in the taxonomy of Micrococcaceae. J. Gen.
Microbiol., 54, 365-380.
12.
J. Green, J. Bunyan, M.A. Cawthorne, and A. T. Diplock (1969). Vitamin E and
hepatotoxic agents 1. Carbon tetrachloride and lipid peroxidation in the rat. Br. J.
Nutr., 23, 297-307.
13.
J. Bunyan, M.A. Cawthorne, A.T. Diplock and J. Green (1969). Vitamin E and
hepatotoxic agents 2. Lipid peroxidation and poisoning with orotic acid, ethanol and
thioacetamide in rats. Br. J. Nutr., 23, 309-317.
14.
M.A. Cawthorne, J. Bunyan, M.V. Sennitt, J. Green and P. Grasso (1970). Vitamin E
and hepatotoxic agents 3. Vitamin E, synthetic antioxidants and carbon tetrachloride
toxicity in the rat. Br. J. Nutr., 24, 357-384.
15.
M.A. Cawthorne, Eileen D. Palmer, J. Bunyan and J. Green (1970). In vivo effects of
carbon tetrachloride and chloroform on liver and kidney glucose-6-phosphatase in
mice. Biochem. Pharmacol., 20, 494-496.
16.
M.A. Cawthorne, Elspeth A. Murrell, J. Bunyan, J.W.G. Leiper, J. Green and J.H.
Watkins (1971). The effect of ethoxyquin on the mortality of sheep treated with DDT
and carbon tetrachloride. Res. Vet. Sci., 12, 516-520.
17.
Sandra D. Atkin, Eileen D. Palmer, P.D. English, B. Morgan, M.A. Cawthorne and J.
Green (1972). The role of cytochrome P-450 in cholesterol biogenesis and
catabolism. Biochem. J., 128, 237-242.
18.
M.A. Cawthorne, Eileen D. Palmer and J. Green (1973). Effect of 6-Ethoxy
2,2,4-trimethyl-1,2-dihydro-quinoline-(ethoxyquin) on carbon tetrachloride metabolism
in the rat. Biochem. Pharmcol., 22, 783-788.
19.
M.A. Cawthorne, Eileen D. Palmer and J. Green (1973). Effect of ethoxyquin in the
carbon tetrachloride-induced changes in rat hepatic microsomal enzymes. Biochem.
Pharmacol., 22, 2066-2068.
20.
Eileen D. Palmer and M.A. Cawthorne (1974). The effects of 1-alkylimidazoles on
hepatic drug-metabolizing enzyme activity. Xenobiotica, 4, 209-217.
21.
J. Bunyan, Elspeth A. Murrell, M.A. Cawthorne and B.T. Redman (1974). Studies in
unidentified growth factors. Factor G, a growth factor for rats. Br. J. Nutr., 31,
167-178.
22.
J. Bunyan, Elspeth A. Murrell, M.A. Cawthorne and B.T. Redman (1974). Studies in
unidentified growth factors 2. Progression, a growth factor for chicks. Br. J. Nutr., 31,
179-184.
23.
M.A. Cawthorne, Eileen D. Palmer and J. Green (1976). Adjuvant-induced arthritis
and drug metabolizing enzymes. Biochem. Pharmacol., 25, 2683-2688.
24.
Anne Beloff-Chain, S. Bogdanovic and M.A. Cawthorne (1977). Influence of fasting
on basal and pituitary stimulated insulin secretion from perfused islet cells of lean and
obese mice. FEBS Lett., 76, 290-293.
25.
Sharon Cornish and M.A. Cawthorne (1978). Fatty acid synthesis in mice during the
24h cycle and during meal feeding. Horm. Metab. Res., 10, 286-290.
26.
M.A. Cawthorne and S. Cornish (1979). Lipogenesis in vivo in lean and genetically
obese (ob/ob) mice fed on diets with a high fat content. Int. J. Obesity, 3, 83-90.
27.
G.Y. Ma, C.D. Gove, M.A. Cawthorne and D.A. Hems (1979). Catabolic effects of
adrenaline and angiotensin II in the perfused liver of normal and genetically obese
(ob/ob) mice. Clin. Sci., 56, 493-499.
28.
Anne Beloff-Chain, S. Bogdanovic and M.A. Cawthorne (1979). Acute regulation of
insulin release by the pituitary gland in relation to hyperinsulinaemia and obesity. J.
Endocrinol., 81, 271-279.
29.
C.G. Wilson, D.V. Parke, J. Green and M.A. Cawthorne (1979). Inhibition of
thiabendazole metabolism in the rat. Xenobiotica, 6, 343-351.
30.
J.R.S. Arch, A. Green and M.A. Cawthorne (1979). Effects of acetylene dicarboxylate: relationship between decreased carcass lipid and increased liver size
and lean body weight. Int. J. Obesity, 3, 289-299.
31.
J.R.S. Arch, A. Green and M.A. Cawthorne (1980). Effects of nafenopin,
diphenylhydantoin, phenobarbitone and some acetylenes on body composition: is
there a relationship between decreased carcass lipid and increased liver size and
induction of drug metabolizing enzymes? Int. J. Obesity, 4, 1-10.
32.
Anne Beloff-Chain, N. Billingham and M.A. Cawthorne (1980). Stimulation of insulin
secretion from mouse pancreatic islets, maintained in tissue culture, by the pituitary
neurointermediate lobe of the genetically obese mouse (ob/ob). Biochem. Biophys.
Res. Commun., 95, 792-795.
33.
M.W. Edwards, S.L. Brooks, C.D. Gove, D.A. Hems and M.A. Cawthorne (1981).
Effect of vasopressin on lipogenesis in obese mice. FEBS Lett., 127, 25-27.
34.
Marjorie A. Hollands and M.A. Cawthorne (1981). Important sites of lipogenesis other
than liver and white adipose tissue. Biochem. J., 196, 645-647.
35.
M.W. Edwards, M.A. Cawthorne and D.H. Williamson (1981). Impairment of effects
of vasopression on [1-14C]oleate metabolism in hepatocytes from obese (ob/ob)
mice. Biochem. J., 198, 239-242.
36.
Marjorie A. Hollands, J.R.S. Arch and M.A. Cawthorne (1981). A simple apparatus
for comparative measurements of energy expenditure in human subjects: the thermic
effect of caffeine. Am. J. Clin. Nutr., 34, 2291-2294.
37.
M.A. Cawthorne and J.R.S. Arch (1982). The search for peripherally acting drugs for
the treatment of obesity - a review. Int. J. Obesity, 6, 1-10.
38.
J.R.S. Arch, A.T. Ainsworth and M.A. Cawthorne (1982). Thermogenic and anorectic
effects of ephedrine and congeners in mice and rats. Life Sci., 30, 1817-1826.
39.
N. Billingham, A. Beloff-Chain and M.A. Cawthorne (1982). Identification of -cell
tropin, a peptide of the pars intermedia which stimulates insulin secretion, in plasma
from genetically obese (ob/ob) mice. J. Endocrinol., 94, 125-130.
40.
M.A. Cawthorne (1982). Metabolic aspects of obesity. Mol. Aspects Med., 5,
295-400.
41.
M.A. Cawthorne (1983). Brown adipose tissue, hibernation and obesity. J. Roy. Soc.
Med., 76, 173-174.
42.
S.A. Smith, M.A. Cawthorne, A.L. Levy and D.L. Simson (1983). Defective activation
by glucose of hepatic glycogen synthesis in the obese hyperglycaemic mouse.
Biochem. J., 216, 491-494.
43.
J.R.S. Arch, A.T. Ainsworth, M.A. Cawthorne, V. Piercy, M.V. Sennitt, V.E. Thody, C.
Wilson and S. Wilson (1984). Atypical -adrenoceptor on brown adipocytes as target
for anti-obesity drugs. Nature, 309, 163-165.
44.
P. Young, M.A. Cawthorne, A.L. Levy and K. Wilson (1984). Reduced maximum
capacity of glycolysis in brown adipose tissue of genetically obese, diabetic (db/db)
mice and its restoration following treatment with a thermogenic 3-adrenoceptor
agonist. FEBS Lett., 176, 16-20.
45.
M.V. Sennitt, J.R.S. Arch, A.L. Levy, D.L. Simson, S.A. Smith and M.A. Cawthorne
(1985). Anti-hyperglycaemic action of BRL 26830, a novel -adrenoceptor agonist, in
mice and rats. Biochem. Pharmacol., 34, 1279-1285.
46.
S.A. Smith, A.L. Levy, M.V. Sennitt, D.L. Simson and M.A. Cawthorne (1985). Effects
of BRL 26830, a novel -adrenoceptor agonist, on glucose tolerance, insulin
sensitivity and glucose turnover in Zucker (fa/fa) rats. Biochem. Pharmacol., 34,
2425-2429.
47.
R.A. J Challiss, L. Budhoski, E.A. Newsholme, M.V. Sennitt and M.A. Cawthorne
(1985). Effect of a novel thermogenic -adrenoceptor agonist (BRL 26830) on insulin
resistance in soleus muscle from obese Zucker rats. Biochem. Biophys. Res.
Commun., 128, 928-935.
48.
P. Young, M.A. Cawthorne and S.A. Smith (1985). Brown adipose tissue is a major
site of glucose utilization in C57Bl/6 ob/ob mice treated with a thermogenic
-adrenoceptor agonist. Biochem. Biophys. Res. Commun., 130, 241-248.
49.
M.J. Carroll, C.A. Lister, M.V. Sennitt, N. Stewart-Long and M.A. Cawthorne (1985).
Improved glycaemic control in C57Bl/6 ob/ob mice after treatment with the
thermogenic -adrenoceptor agonist, BRL 26830. Diabetes, 34, 1198-1204.
50.
P. Young, L. King and M.A. Cawthorne (1985). Increased insulin binding and glucose
transport in white adipocytes isolated from C57Bl/6 ob/ob mice treated with the
thermogenic -adrenoceptor agonist BRL 26830. Biochem. Biophys. Res. Commun.,
133, 457-461.
51.
S.A. Smith, M.A. Cawthorne and D.L. Simson (1986). Glucose metabolism in the
obese hyperglycaemic (C57Bl/6 ob/ob) mouse: The effects of fasting on glucose
turnover rates. Diabetes Res., 3, 83-86.
52.
S.A. Smith, P. Young and M.A. Cawthorne (1986). Quantification in vivo of the
effects of insulin on glucose utilization in individual tissues of warm- and
cold-acclimatized rats. Biochem. J., 237, 789-795.
53.
J.M. Fyles, M.A. Cawthorne and S.L. Howell (1986). The characteristics of
-adrenergic binding sites on pancreatic islets of Langerhans. J. Endocrinol., 111,
263-270.
54.
J.M. Fyles, M.A. Cawthorne and S.L. Howell (1987). The determination of alphaadrenergic receptor concentration on rat pancreatic islet cells. Biosci. Rep., 7, 17-22.
55.
R.E. Almond, M.A. Cawthorne and M. Enser (1988). Muscles of diabetic (db/db)
mice: fibre size, fibre type and the effects of a thermogenic, -adrenoceptor agonist.
Int. J. Obesity, 12, 81-91.
56.
T.H. Mitchell, R.D.M. Ellis, S.A. Smith. G.A. Robb and M.A. Cawthorne (1989).
Effects of BRL 35135, a beta-adrenoceptor agonist with novel selectivity, on glucose
tolerance and insulin sensitivity in obese subjects. Int. J. Obesity, 13, 757-766.
57.
P. Young, J. Berge, H. Chapman and M.A. Cawthorne
adrenoceptor antagonists show selectivity for 2A- and 2B-adrenoceptor subtypes.
Eur. J. Pharmacol., 168, 381-386.
58.
P. Young, D.M. Kirkham, G.L. Murphy and M.A. Cawthorne (1991). Evaluation of
inhibitory guanine nucleotide regulatory protein Gi function in hepatocyte and liver
membranes from obese Zucker (fa/fa) rats and their lean (Fa/?) littermates.
Diabetologia, 34, 565-569.
59.
M. Davenport, J L. Morton, A. Beloff-Chain, S. J. Dunmore and M.A. Cawthorne
(1991). The effect of insulin and pituitary peptide beta cell tropin on the incorporation
of D-3-3H-glucose into lipid in brown adipose tissue from lactating and non-lactating
rats. Biochem. Biophys. Res. Commun., 181, 1437-1441.
60.
S.P. Roberts, J. Kelly, M.A. Cawthorne and M.V. Sennitt (1992). SK&F 104078, a
post-junctionally selective 2-adrenoceptor antagonist in human saphenous vein in
vitro. Naunyn-Schmiedeberg's Pharmacol., 345, 327-332.
61.
S.J. Dunmore, M.A. Cawthorne, D.C.J. Hislop, J.L. Morton and A. Beloff-Chain
(1993). -cell tropin and glucose-induced hypersecretion of insulin and amylin from
perfused fatty rat pancreas. J. Endocrinol., 137, 375-381.
62.
G.M. Murphy, D. Kirkham, M.A. Cawthorne and P. Young (1993). Correlation of
-adrenoceptor activation of cyclic AMP dependent protein kinase with activation of
lipolysis. Biochem. Pharmacol., 46, 575-581.
63.
B.C.C. Cantello, M.A. Cawthorne, G.P. Cottam, P.T. Duff, D. Haigh, R.M. Hindley,
C.A. Lister, S.A. Smith and P.L. Thurlby (1994). [[-(heterocyclylamino) alkoxy]
benzyl[-2,4-thiazolidinediones as potent antihyperglycaemic agents. J. Med. Chem.,
37, 3977-3985.
64.
B.C.C. Cantello, M.A. Cawthorne, D. Haigh, R.M. Hindley, S.A. Smith and P.L.
Thurlby (1994). The synthesis of BRL 49653 - a novel and potent antihyperglycaemic agent. Bioorg. Med. Chem. Lett., 4, 1181-1184.
65.
A. Oriowo, M.V. Sennitt, S.A. Smith, R.R. Ruffolo and M.A. Cawthorne (1994). adrenoceptor selectivity profile of BRL 37344 in the pithed rat. J. Autonomic
Pharmacol., 14, 337-344.
66.
P. Muzzin, O. Boss, N. Mathis, J.P. Revelli, J.P. Giacobino, K. Willcocks, G.T.
Badman, B.C.C. Cantello, R.M. Hindley and M.A. Cawthorne (1994).
Characterisation of a highly specific new 3-adrenergic receptor radio-ligand, 3H-SB
206606. Mol. Pharmacol., 46, 357-363.
67.
T.P. Eldershaw, S. Rattigan, K.A. Dora, M.A. Cawthorne, R.E. Buckingham, E.Q.
Colquhoun and M.G. Clark (1994). Altered regulation of thermogenesis in the obese
Zucker hindlimb. Can. J. Biochem., 72, 1567-1573.
68.
G. Ibrahimi, L. Treboul, D. Gailliard, E.Z. Amri, G. Ailhaud, P. Young, M.A. Cawthorne
and P. Grimaldi (1994). Evidence for a common mechanism of action of fatty acids
and anti-diabetic agents thiazolidinediones on gene expression in pre-adipose cells.
Mol. Pharmacol., 46, 1070-1076.
69.
T.P. Eldershaw, S. Rattigan, M.A. Cawthorne, R.E. Buckingham, E.Q. Colquhoun and
M.G. Clark (1995). Treatment with the thiazolidinedione (BRL 49653) decreases
insulin resistance in the obese Zucker hindlimb. Hormone Metabolic Research, 27,
169-172.
70.
S. Klaus, P. Muzzin, R.P. Revelli, M.A. Cawthorne, J.P. Giacobino and D. Ricquier
(1995). Control of 3-adrenergic receptor gene expression in brown adipocytes in
culture. Mol. Cell. Endocrinol., 109, 189-195.
71.
P.W. Young, M.A. Cawthorne, P.J. Coyle, J.C. Holder, G.D. Holman, I.J. Kozke, D.M.
Kirkham, C.A. Lister and S.A. Smith (1995). Repeat treatment of obese mice with
BRL 49653, a novel and potent insulin sensitiser, enhances insulin action in white
adipocytes in association with increased insulin binding and cell surface glucose
transporter (GLUT4), as measured by photoaffinity labelling. Diabetes 44, 10871092.
72.
M. Davenport, J.L. Morton and M.A. Cawthorne (1995). Changes in plasma beta-cell
tropin concentrations during pregnancy in rats. J. Endocrinology, 146, 177-182.
73.
Y-L. Liu, M.A. Cawthorne and M.J. Stock (1996). Biphasic effects of the adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal
muscle. Br. J. Pharmacol. 117, 1355-1361.
74.
L.J. Beeley and M.A. Cawthorne (1996). Lean Prospects. Chem. Britain, May 31-34.
75.
M.A. Oriowo, H. Chapman, D.M. Kirkham, M.V. Sennitt, R.R. Ruffolo and M.A.
Cawthorne (1996). The selectivity in vitro
agonist BRL 37344. J. Pharmacol. Exp. Therap. 277, 22-27.
76.
C. Deng, A. Paoloni-Giacobino, F. Kuehne, O. Boss, J-P. Revelli, M. Moinat, M.A.
Cawthorne, P. Muzzin and J-P Giacobino (1996). Respective degree of expression of
1
2
3-adrenoceptors in human brown and white adipose tissue. Br. J.
Pharmacol. 118, 929-934.
77.
S.L. Pearson, M.A. Cawthorne, J.C. Clapham, S.J. Dunmore, S.D. Holmes, G.B.T.
Moore, S.A. Smith and M. Tadayyon (1996). The thiazolidinedione insulin sensitiser,
BRL 49653, increases the
2 in adipose tissue of high fat
fed rats. Biochem. Biophys. Res. Commun. 229, 752-757.
78.
V. Emilsson, Y-L. Liu, M.A. Cawthorne, N.M. Morton and M. Davenport (1997).
Expression of the functional leptin receptor mRNA in pancreatic islets and direct
inhibitory action of leptin on insulin secretion. Diabetes 46, 313-316.
79.
Y-L. Liu, V. Emilsson and M.A. Cawthorne (1997). Leptin inhibits glycogen synthesis
in the isolated soleus muscle of obese (ob/ob) mice. FEBS Lett 411, 351-355.
80.
A.L. Pallett, N.M. Morton, M.A. Cawthorne and V. Emilsson (1997). Leptin inhibits
insulin secretion and reduces insulin mRNA levels in rat isolated pancreatic islets.
Biochem. Biophys. Res. Commun. 238, 267-270.
81.
V. Emilsson, R.J. Summers, S. Hamilton, Y-L. Liu and M.A. Cawthorne (1998). The
effects of the 3-adrenoceptor agonist BRL 35153 on UCP isoform mRNA
expression. Biophys. Res. Commun. 252, 450-454.
82.
N.M. Morton, R.P. de Groot, M.A. Cawthorne and V. Emilsson (1999). Interleukin-1
activates a short STAT-3 isoform in clonal insulin-secreting cells. FEBS Letters, 442,
57-60.
83.
N.M. Morton, V. Emilsson, Y-L. Liu and M.A. Cawthorne (1998). Leptin action in
intestinal cells. J. Biol. Chem. 273, 26194-26201.
84.
M.A. Cawthorne, N.M. Morton, A.L. Pallett, Y-L. Liu and V. Emilsson (1998).
Peripheral metabolic actions of leptin. Proc. Nutr. Soc. 57, 449-453.
85.
M.V. Sennitt, A.J. Kaumann, P. Molenaar, L.J. Beeley, P.W. Young, J. Kelly, H.
Chapman, S.M. Henson, J.M. Berge, D.K. Dean, N.R. Kotecha, H.K.A. Morgan, H.K.
Rami, R.W. Ward, M. Thompson, S. Wilson, S.A. Smith, M.A. Cawthorne, M.J. Stock
and J.R.S. Arch (1998). The contribution of classical (1/2) and atypical adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial
appendage contraction by novel 3-adrenoceptor agonists of different selectivities. J.
Pharm. Exp. Therap. 285, 1084-1095.
86.
V. Emilsson, R.J. Summers, S. Hamilton, Y-L. Liu and M.A. Cawthorne (1998). The
effects of the 3-adrenoceptor agonist BRL 35135 on UCP isoform mRNA
expression. Biochem. Biophys. Res. Commun. 252, 450-454.
87.
N.M. Morton, R.P. de Groot, M.A. Cawthorne and V. Emilsson (1999). Interleukin-1
activates a short STAT-3 isoform in clonal insulin-secreting cells. FEBS Lett. 442, 5760.
88.
N.M. Morton, V. Emilsson, R.P. de Groot, A.L. Pallett and M.A. Cawthorne (1999).
Leptin signalling in pancreatic islets and clonal insulin-secreting cells. J. Mol.
Endocrinol. 22, 173-184.
90.
V. Emilsson, J.R.S. Arch, R.P. de Groot, C.A. Lister and M.A. Cawthorne (1999).
Leptin treatment increases suppressors of cytokine signaling in central and peripheral
tissues. FEBS Lett. 455, 170-174.
91.
P.D. Chamberlain, K.H. Jennings, F. Paul, J. Cordell, A. Berry, S.D. Holmes, J. Park,
J. Chambers, M.V. Sennitt, M.J. Stock, M.A. Cawthorne, P.W. Young and G.J.
Murphy (1999). The tissue distribution of the human 3-adrenoceptor studied using a
monoclonal antibody: direct evidence of the 3-adrenoceptor in human adipose
tissue, atrium and skeletal muscle. Int. J. Obes. 23, 1057-1065.
92.
Y-L. Liu, M.V. Sennitt, D.C. Hislop, D.L. Crombie, R.A. Heyman and M.A. Cawthorne
(2000). Retinoid X receptor agonists have anti-obesity effects and improve insulin
sensitivity in Zucker fa/fa rats. Int. J. Obes. 24, 997-1004.
93.
M. Board, P. Doyle and M.A. Cawthorne (2000). BRL 37344, but not CGP 12177,
stimulates fuel oxidation by soleus muscle in vitro. Eur. J. Pharmacol. 406, 33-40.
94.
V. Emilsson, J. O’Dowd, S. Wang, Y-L. Liu, M. Sennitt, R. Heyman and M.A.
Cawthorne (2000). The effects of rexinoids and rosiglitazone on body weight and
uncoupling protein isoform expression in the Zucker fa/fa rat. Metabolism 49, 16101615.
95.
J-C. Sanchez, D. Chiappe, V. Converset, C. Hoogland, P-A. Binz, S. Paesano, R.D.
Appel, S. Wang, M. Sennitt, A. Nolan, M.A. Cawthorne, D.F. Hochstrasser (2001).
The mouse SWISS-2D PAGE database: a tool for proteomics study of diabetes and
obesity. Proteomics 1, 136-163.
96.
V. Emilsson, J. O’Dowd, A.L. Nolan and M.A. Cawthorne (2001). Hexosamines and
nutrient excess induce leptin production and leptin receptor activation in pancreatic
islets and clonal beta-cells. Endocrinology 142(10), 4414-4419.
97.
A.C. Haynes, H. Chapman, C. Taylor, G.B. Moore, M.A. Cawthorne, M. Tadayyon, J.C.
Clapham and J.R.S. Arch (2002). Anorectic, thermogenic and anti-obesity activity of a
selective orexin-1 receptor antagonist in ob/ob mice. Regulatory Peptides 104, 153-159.
98.
S. Wang, M.A. Cawthorne and J.C. Clapham (2002). Enhanced diabetogenic effect of
streptozotocin in mice overexpressing UCP-3 in skeletal muscle. Ann. N.Y. Acad. Sci.
967, 112-119.
99.
J-C. Sanchez, V. Converset, A. Nolan, G. Schmid, S. Wang, M. Heller, M.V. Sennitt, D.F.
Hochstrasser, and M.A. Cawthorne (2002). Effect of rosiglitazone on the differential
expression of diabetes-associated proteins in pancreatic islets of C57Bl/6 lep/lep mice.
Mol. Cell. Proteomics 1, 509-516.
100.
S. Wang, A. Subramaniam, M.A. Cawthorne and J.C. Clapham (2003). Increased fatty
acid oxidation in transgenic mice overexpressing UCP3 in skeletal muscle. Diabetes,
Obes. Metab. 5, 295-301.
101.
J.C. Sanchez, V. Converset, A. Nolan, G. Schmid, S. Wang, M. Heller, M.V. Sennitt, D.F.
Hochstrasser and M.A.Cawthorne (2003). Effect of rosiglitazone on the differential
expression of obesity and insulin resistance associated proteins in lep/lep mice.
Proteomics 3,1500-1520.
102.
C. Stocker, J. O'Dowd, N.M. Morton, E. Wargent, M.V. Sennitt, D. Hislop, S. Glund, J.R.
Seckl, J.R.S. Arch and M.A. Cawthorne (2004). Modulation of susceptibility to weight
gain and insulin resistance in low birthweight rats by treatment of their mothers with leptin
during pregnancy and lactation. Int. J. Obes. Relat. Metab. Disord. 28, 129-136.
Published online 14 October 2003.
103.
G.M. Schmid, V.Converset, N.Walter, M.V. Sennitt, K.-.Y Leung, H. Byers, M. Ward, D.F.
Hochstrasser, M.A. Cawthorne and J.C. Sanchez (2004). Effect of high-fat diet on the
expression of proteins in muscle, adipose tissues, and liver of C57Bl/6 mice. Proteomics
4, 2270-2282. Published online 21 June 2004.
104.
E. Wargent, M.V. Sennitt, C. Stocker, A.E. Mayes, L. Brown, J. O’Dowd, S.J.Y. Wang,
A.W.C. Einerhand, I. Mohede, J.R.S. Arch and M.A. Cawthorne (2005). Prolonged
treatment of genetically obese mice with conjugated linoleic acid improves glucose
tolerance and lowers plasma insulin concentration: possible involvement of PPAR
activation. Lipids Health Dis., 4, 3. Published 10 January 2005.
105.
E. Wargent, C. Stocker, P. Augstein, P. Heinke, A. Meyer, T. Hoffmann, A. Subramanian,
M.V. Sennitt, H.-U. Demuth, J.R.S. Arch and M.A. Cawthorne (2005). Improvement of
glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl
peptidase inhibitor P32/98: comparison with and combination with rosiglitazone. Diabetes
Obes. Metab., 7(2), 170–181.
106.
C.J. Stocker, J.R.S. Arch and M.A. Cawthorne (2005). Fetal origins of insulin resistance
and obesity. Proc. Nutr. Soc. 64(2), 143–151.
107.
S.J. Wang, C. Cornick, J. O'Dowd, M.A. Cawthorne and J.R Arch (2007). Improved
glucose tolerance in acyl CoA:diacylglycerol acyltransferase 1-null mice is dependent
on diet. Lipids Health Dis. 6, 2.
108.
C.J. Stocker, E. Wargent, J. O’Dowd, C. Cornick, J.R. Speakman, J.R.S. Arch and
M.A. Cawthorne. Prevention of diet-induced obesity and impaired glucose tolerance in
rats following administration of leptin to their mothers. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 292(5), R1810-1818.
109.
G.M. Schmid, P. Meda, D. Caille, E. Wargent, J. O’Dowd, D.F. Hochstrasser, M.A.
Cawthorne and J-C. Sanchez (2007). Inhibition of insulin secretion by betagranin, a
N-terminal chromogranin A fragment. J. Biol. Chem. 282(17), 12717-24.
110.
R.A. Ngala, J. O’Dowd, S.J. Wang, A. Agarwal, C. Stocker, M.A. Cawthorne, J.R.S.
Arch (2006). Metabolic responses to BRL37344 and clenbuterol in soleus muscle
and C2C12 cells via different atypical pharmacologies and β2-adrenoceptor
mechanisms. Br. J. Pharmacol. 55(3), 395–406;e-pub 16 June 2008.
doi:10.1038/bjp.2008.244
111.
C.J. Stocker, M.A. Cawthorne (2008). The influence of leptin on early life
programming of obesity. Trends Biotechnol. 26(10), 545–551. e-pub ahead of print
14 August 2008. doi:10.1016/j.tibtech.2008.06.004
112.
C.L. Cornick, B.H. Strongitharm, G. Sassano, C. Rawlins, A.E. Mayes, A.N. Joseph,
J. O’Dowd, C. Stocker, E. Wargent, M.A. Cawthorne, A.L. Brown, J.R.S. Arch.
Identification of a novel agonist of peroxisome proliferator-activated receptors alpha
and gamma that may contribute to the anti-diabetic activity of guggulipid in
Lep(ob)/Lep(ob) mice. J. Nutr. Biochem. e-pub ahead of print 14 October 2008.
doi:10.1016/j.jnutbio.2008.07.010
II. Abstracts
1.
L.R. Jeffries, M.A. Cawthorne, M. Harris, A.T. Diplock, J. Green and S.A. Price
(1967). Menaquinone patterns of micrococcaceae: their possible taxonomic
significance. Spisy, 230.
2.
M.A. Cawthorne, L.R. Jeffries, M. Harris, S.A. Price, A.T. Diplock and J. Green
(1967). Menaquinone-4 and -5 in a Bacterium. Biochem. J., 1104, 35c-36c.
3.
C.G. Wilson, D.V. Parke and M.A. Cawthorne (1972). Investigation of the
5-hydroxylation of Thiabendazole in Rat Liver Microsomal Preparation. Biochem.
Soc. Trans., 1, 195-196.
4.
M.A. Cawthorne and S. Cornish (1978). The effect of high fat diets on lipogenesis in
liver and adipose tissue in lean and genetically obese mice. (Abs. 2nd Int. Congress
on Obesity) published in Int. J. Obesity, 2, 472.
5.
M.A. Cawthorne and J.R.S. Arch (1980). Blockade of the thermic effect of a meal in
mice by dopamine, 5-HT and noradrenaline receptor antagonists. Alimentazine
nutrizime metabolism, 1, 240 (abstract).
6.
D.H. Williamson, M.C. Sugden, M.W. Edwards and M.A. Cawthorne (1981).
Comparison of the effects of vasopression on [1-14C]oleate metabolism in
hepatocytes from rats, and lean and obese (ob/ob) mice. Proc. Australian Biochem.
Soc., 14, Q4 (abstract).
7.
M.A. Cawthorne and J.R.S. Arch (1981). Measurement of the thermogenic effect of
food in lean and obese (ob/ob) mice. Int. J. Obesity, 5, 383 (abstract).
8.
N Billingham, A. Beloff-Chain and M.A. Cawthorne (1982). Increased levels of -cell
tropin in plasma of congenitally obese (ob/ob) mice. Int. J. Obesity, 6, 217 (abstract).
9.
M.A. Cawthorne, M.V. Sennitt, S.A. Smith, D.L. Simson and J.R.S. Arch (1983).
Anti-hyperglycaemic action of BRL 26830A in animal models of diabetes. In Proc. of
Int. Workshop `Lessons from Animal Diabetes'.
10.
K.L. Wilson, S.A. Smith and M.A. Cawthorne (1984). Comparative effects of
voluntary exercise and caloric restriction on body composition and glucose tolerance
in Zucker (fa/fa) rats. Int. J. Obesity, 8, 381 (abstract).
11.
P. Young, L. King, M.V. Sennitt and M.A. Cawthorne (1984). Brown adipose tissue: a
major site of glucose utilization in the cold-acclimated guinea-pig. Int. J. Obesity, 8,
471 (abstract).
12.
P. Jones, M. Ashwell and M.A. Cawthorne (1985). The effect of preweaning underand over-nutrition on rat brown adipose tissue thermogenic capacity. Int. J. Obesity,
9, 228-229 (abstract).
13.
M.V. Sennitt, S.A. Smith and M.A. Cawthorne (1986). Anti-hyperglycaemic activity in
rats and mice of BRL 35135, a novel -adrenoceptor agonist. Diabetes, 35, abs 262.
14.
M.A. Cawthorne, P. Young and S.A. Smith (1986). Effects of BRL 35135, a novel
type of -adrenoceptor agonist, on glucose tolerance and insulin sensitivity in obese
Zucker rats. Diabetes, 35, abs 263.
15.
S.A. Smith, M.A. Cawthorne, L. Fay, D. McCullough and T.H. Mitchell (1987). Effect
of BRL 26830A a novel -adrenoceptor agonist on insulin sensitivity in lean healthy
male volunteers. Diabetes, 36, abs; 8 (abstract).
16.
S.A. Smith, S.C. Pratt, P. Young and M.A. Cawthorne (1987). Pharmacotherapy in a
non-genetic, non-obese rat model of type II diabetes. Abstract 345 at Lessons from
Animal Diabetes II (abstract).
17.
M.A. Cawthorne, M.V. Sennitt, S.A. Smith and P. Young (1987). Effects of BRL
35135, a novel -adrenoceptor agonists, on insulin secretion and action. Abstract
344 at Lessons from Animal Diabetes II (abstract).
18.
C. Wilson, R.E. Buckingham, S. Mootoo, L.S. Parrott, T.C. Hamilton, S.C. Pratt and
M.A. Cawthorne (1988). In vivo and in vitro studies of cromakalim (BRL 34915) and
glibenclamide in the rat. Br. J. Pharmacol., 93, 126p (abstract).
19.
T. Mitchell, G. Robb, M. Cawthorne, R. Ellis and S. Smith (1988). Effects of BRL
35135, a novel -adrenoceptor agonist, on oral glucose tolerance in obese patients.
Diabetic Medicine (abs). 5, 39
20.
T. Mitchell, S. Smith, G. Robb, T. Hendra, R. Ellis and M. Cawthorne (1988). Effects
of BRL 35135, a novel -adrenoceptor agonist on insulin-mediated glucose disposal
in type II diabetic patients. Diabetic Medicine (abs), 5, 17.
21.
C. Wilson, T.C. Hamilton and M.A. Cawthorne (1989). Antagonism of vaso-relaxation
to cromakalim and BRL 38227 by non-sulphonylurea hypoglycaemic agents. Br. J.
Pharmacol., 98, Suppl Oct, p723.
22.
S.A. Smith, C. Zed, D. McCullough, G. Harris and M.A. Cawthorne (1989).
Thermogenic activity in man of BRL 35135: a potent and selective atypical
-adrenoceptor agonist. Int. J. Obesity, 13, Suppl 1, 133 (abstract).
23.
G.J. Murphy, D.M. Kirkham, M.A. Cawthorne and P. Young (1990). Assessment of Gi
function in an animal model of non-insulin dependent diabetes. Biochem. Trans., 18,
1289-1290.
24.
D.M. Kirkham, G.J. Murphy, M.A. Cawthorne, and P. Young (1991). Gi function and
the streptozotocin-treated rat. Biochem. Trans.
25.
J.C. Holder, M.A. Cawthorne, G.J.S. Cooper, P.J. Coyle, T.J. Rink and S.A. Smith
(1991). Acute effects of amylin on hepatic and peripheral insulin action in the rat.
Diabetologia, 34, suppl. 2, Ab. 414.
26.
S.J. Dunmore, M.A. Cawthorne and A. Beloff-Chain (1991). Amylin and insulin
secretion induced by beta cell tropin and glucose from perfused pancreas of fatty
(fa/fa) and lean (Fa/?) rats. Endocrinology, abs.
27.
P.W. Young, M.A. Cawthorne, P.J. Coyle, J.C. Holder, G.D. Holman, I.J. Kozka, D.
Kirkham and S.A. Smith (1993). Chronic treatment of ob/ob mice with BRL 49653
enhances insulin stimulated translocation of GLUT-4 to the adipocyte cell surface.
Diabetologia, 36, Supplement 1, A75, 285.
28.
S.A. Smith, M.A. Cawthorne, P.J. Coyle, J.C. Holder, D. Kirkham, C.A. Lister, G.J.
Murphy and P.W. Young (1993). BRL 49653 normalises glycaemic control in Zucker
fa/fa rats by improving hepatic and peripheral sensitivity to insulin. Diabetologia, 36,
Supplement 1, A184, 707.
29.
M.A. Cawthorne, C.A. Lister, J.C. Holder, D.M. Kirkham, P. Young, B.C.C. Cantello,
R.M. Hindley and S.A. Smith (1993). Anti-hyperglycaemic efficacy of BRL 49653, a
highly potent thiazolidinedione, in animal models of non-insulin dependent diabetes.
(American Diabetes Association), Diabetes, 42, suppl. 1, 204A.
30.
M.V. Sennitt, P. Young, D. Kirkham, S.A. Smith and M.A. Cawthorne (1994). Multiple
lipolytic -adrenoceptor sub-types in human adipose tissue: demonstration of a
functional 3-adrenoceptor using CGP 12177. ((1994) 7th International Congress on
Obesity, Canada), Int. J. Obesity, 18, suppl. 2, Abs P69, 19.
31.
M. Moinat, C. Deng, G. Paolomi, F. Kuhne, J.P. Revelli, P. Muzzin, M.A. Cawthorne
and J.P. Giacobino (1994). Degree of expression of 1, 2 and 3-adrenergic
receptors in human white and brown adipose tissues. (Satellite to 7th International
Congress on Obesity, Quebec.)
32.
T.P. Eldershaw, S. Rattigan, M.A. Cawthorne, R.E. Buckingham, E.Q. Colquhoun and
M.G. Clark (1994). Prior treatment of obese Zucker rats with the thiazolidinedione
(BRL 49653) decreases insulin resistance in perfused hindlimb. (Satellite to 7th
International Congress on Obesity, Boston.)
33.
J. Kelly, M.V. Sennitt, S.A. Smith and M.A. Cawthorne (1994). Evidence for a
functional ß3-adrenoceptor in human taenia coli. (Satellite to Int. Union of
Pharmacology, Philadelphia.)
34.
M. Davenport, S.J. Dunmore, D.C. Hislop, D.H. Coy and M.A. Cawthorne (1995).
Inhibitory action of somatostatin on insulin secretion by perfused rat pancreas is
mediated by a Type 5 receptor. Diabetes, 44, Suppl 1, Abs 123.
35.
M. Davenport, N. Cheung, S.J. Dunmore, D.H. Coy and M.A. Cawthorne (1995).
Somatostatin type 5 receptors mediate the inhibitory action of somatostatin on insulin
secretion in Zucker fatty rat perfused pancreas. Diabetologia, 36. Suppl 1, Abs 410,
A106.
36.
Y-L. Liu, M.J. Stock and M.A. Cawthorne
-adrenoceptor.
Int.
J.
Obesity,
20,
Suppl
4, Abs
3
08-186-WPI, p. 72.
37.
M.A. Cawthorne, Y-L. Liu, Morton, N., Davenport, M. and Emilsson, V. (1997). Is
there a role for leptin in the development of NIDDM? Diabetic Med.
38.
Y-L. Liu, V. Emilsson, and M.A. Cawthorne (1997). Inhibition of glycogen synthesis
by leptin in isolated soleus muscle of obese (ob/ob) mice. Int. J. Obesity. 21, Suppl 2,
23, S13.
39.
V. Emilsson, N. Cheung, M.V. Sennitt and M.A. Cawthorne (1997). Melanin
concentrating hormone stimulates leptin secretion from adipocytes. Diabetologia, 40,
Suppl 1, 678, A173.
40.
S. Pearson, M.A. Cawthorne, J.C. Clapham, S.J. Dunmore, S.D. Holmes, G.B.T.
Moore, S.A. Smith and Tadayyon, M. (1997). The insulin sensitiser, BRL 49653,
increases expression of PPAR- and aP2 mRNA but does not effect UCP or 3-AR
mRNA. Int. J. Obesity, 21, Suppl 2, 180, S61.
41.
A.L. Pallett, N.M. Morton, V. Emilsson and M.A. Cawthorne (1997). Effect of leptin on
glucose stimulated insulin secretion in isolated rat islets. Exp. Clin. Endocrinol.
Diabetes, 105, 4, A41.
42.
N.M. Morton, V. Emilsson, A.L. Pallett and M.A. Cawthorne (1997). Leptin-induced
tyrosine phosphorylation in islets from ob/ob mice. Exp. Clin. Endocrinol. Diabetes,
105, 4, A35.
43.
N.M. Morton, V. Emilsson and M.A. Cawthorne (1998). Interleukin 1 induces a novel
STAT-DNA binding activity in the insulin secreting cell line Rim m5F. Keystone
meeting, JAK and STAT signalling (February).
44.
N.M. Morton, V. Emilsson, A.L. Pallett and M.A. Cawthorne (1998). Leptin signalling
in pancreatic beta cells. British Diabetic Association, Edinburgh (March).
45.
S.A. Smith, D. Boam, D. Betherton-Watt, M.A. Cawthorne, G. Moore, S.
Loughborough, J. Warrack, M. Wilkinson & C.A.Lister (1998). Rosiglitazone
increases pancreatic islet cell area, density and insulin content, but not insulin gene
expression. Diabetes 47, Suppl 1, A18, Abs 0072.
46.
S.A. Smith, D. Boam, M.A. Cawthorne, J. Sidaway, M. Newman, M. Wilkinson, S.
Dunmore, C.A. Lister (1998). Rosiglitazone improves insulin sensitivity and reduces
hyper-expression of insulin and amylin mRNAs in pancreatic islets. Diabetes 47,
Suppl 1, A94, Abs 0365.
47.
Y-L. Liu, M.V. Sennitt, D.C. Hislop, D.L. Crombie, R.A. Heyman and M.A. Cawthorne
(1998). Rexinoid x receptor agonists improve insulin sensitivity and have antiobesity
effects in Zucker fa/fa rats. Diabetes 47, Suppl 1, A283, Abs 1099.
48.
M. Board and M.A. Cawthorne (1998). Abnormal response of glucose uptake by
soleus muscle from ob/ob mice to BRL 37344. Int. J. Obesity 22, Suppl 3, S189, Abs
p355.
49.
M.A. Cawthorne, P.D. Chamberlain, K.H. Jennings, F. Paul, J. Cordell, A. Berry, S.D.
Holmes, J. Park, J. Chambers, M.V. Sennitt, M.J. Stock, P.W. Young and G.J.
Murphy (1998). Direct evidence of a 3-adrenoceptor expression in human adipose
tissue, atrium and skeletal muscle obtained using a novel monoclonal antibody. Int.
J. Obesity 22, Suppl 3, S74, Abs 0267.
50.
M.A. Cawthorne (1998). Thiazolidinediones in the treatment of Insulin Resistance
Syndrome. Int. J. Obesity 22, Suppl 3, S86, Abs 0314.
51.
V. Emilsson, J. Arch, R.P. De Groot, A.M. Kanu, Y-L. Liu, N.M. Morton, A.L. Pallett
and M.A. Cawthorne (1998). A role for suppressors of leptin signalling in the states of
leptin resistance. Satellite of 8th International Congress on Obesity, Paris (August).
52.
A. Pallett, V. Emilsson, D. Coy, J. Taylor and M.A. Cawthorne (1998). Reduced
expression of somatostatin receptor sub-types in Zucker rat islets and functional
typing of the somatostatin reduced inhibition of insulin secretion. Diabetologia 41,
Suppl 1, A152, Abs 592.
53.
S.A. Smith, D. Boam, M.A. Cawthorne, J. Sidaway, M. Newman, M. Wilkinson, S.
Dunmore and C.A. Lister (1998). Rosiglitazone reduces overexpression of insulin
and amylin mRNA in hypertrophied pancreatic islets. Diabetologia 41, Suppl 1, A169,
abs 659.
54.
C.A. Lister, D. Boam, D. Bretherton-Watt, M.A. Cawthorne, G.Moore, S.
Loughborough, J. Warrack, M. Wilkinson and S.A. Smith (1998). Rosiglitazone
increases pancreatic islet cell area, number and insulin content, but not insulin gene
expression. Diabetologia 41, Suppl 1, A169, Abs 660.
55.
M. Board, P. Doyle and M.A. Cawthorne (1999). Stimulation of oxidative metabolism
of isolated skeletal muscle by 3-adrenoceptor (3-AR) agonists: evidence for the
existence of a novel -AR in murine soleus muscle. Diabetes 48, Suppl 1, Abs 1991.
56.
V. Emilsson, J. O’Dowd, S. Wang, R. Heyman and M. Cawthorne (1999). Effects of
rexinoids and thiazolidinedione on levels of UCP isoforms and PGC-1 in the obese
Zucker rat. Diabetologia 42, Suppl 1, A 206, Abs 774.
57.
M. Board, F. Preitner, J-P. Giacobino and M.A. Cawthorne (2000). The 3adrenoceptor agonist, BRL 37344, increases pyruvate and palmitate oxidation in
soleus muscle of 3-KO mice. Int. J. Obesity 24, Suppl 1, Abs 80, S30.
58.
A.C. Haynes, B. Jackson, M.A. Cawthorne, S. Wilson, M. Tadayyon and J.R.S. Arch
(2000). Interactions of the orexins and melanin concentrating hormone on feeding.
Int. J. Obesity 24, Suppl 1, Abs 101, S37.
59.
J-C. Sanchez, V. Rouge, D. Hochstrasser, M.V. Sennitt, S. Wang, A.L. Pallett and
M.A. Cawthorne (2000). Effect of rosiglitazone on the differential expression of
diabetes associated proteins in pancreatic islets of C57BI/6J lep/lep mice. Diabetes
49, Suppl 1, Abs 1041-P, A250.
60.
E. Wargent, A.L. Nolan, Y. Shen, J. Dong, J.E. Taylor, M. Culler, B. Morgan, C-W.
Woon and M.A. Cawthorne (2000). Insulin secretagogue activity in vitro and in
perfused pancreas of dipeptidase IV resistant GLP-1 analogues. Diabetologia 43,
Suppl 1, A 137, Abs. 532.
61.
A.L. Nolan, M.V. Sennitt, E.B. Whittle, C.J. Stocker and M.A. Cawthorne (2000).
Acute and chronic effects of exendin-4 on glycaemic control and food intake in
diabetic mice. Diabetologia 43, Suppl 1, A 148, Abs. 572.
62.
M.A. Cawthorne, K. Clavurier, C. Stocker, E. Whittle, A. Subramaniam, I. Rubin and
M.V. Sennitt (2000). P57, a plant derived anorexic agent, reduces food intake and
normalises blood glucose in ZDF rats. Obesity Research 8, Suppl 1, 81S, Abs.
PB55.
63.
J.-C. Sanchez, D. Chiappe, M.V. Sennitt, V. Rouge, S. Wang, A.L. Pallett, D.
Hochstrasser and M. Cawthorne (2000). Effects of the insulin sensitiser drug,
rosiglitazone, on the differential expression of obesity-associated liver cytosolic and
nuclear proteins of lep/lep mice. Obesity Research 8, Suppl 1, 125S, Abs. PF38.
64.
A. Subramaniam, C. Stocker, M.V. Sennitt, S. Wang, A.L. Nolan, L. Brown, M. Bertrand,
A. Peilow, A. Mayes and M.A. Cawthorne (2001). Guggul lipid reduces insulin resistance
and body weight gain in C57Bl/6 lep/lep mice. Int. J. Obesity 25, Suppl. 2, S24, Abs.
O66.
65.
V. Emilsson, J. O’Dowd, A.L. Pallett and M.A. Cawthorne (2001). Hexosamine and
nutrient excess induce leptin production and leptin receptor activation in islet  cells.
Diabetes 50, Suppl. 2, A343, Abs. 1428.
66.
C. Stocker, E. Wargent, A. Subramaniam, H-U. Demuth, M. Sennitt and M.A. Cawthorne
(2001). The dipeptidyl peptidase IV inhibitor P32/98 improves glucose tolerance in
diabetic ZDF rats. Diabetes 50, Suppl. 2, A522, Abs. 2200.
67.
E.T. Wargent, M.V. Sennitt, C.W. Woon and M.A. Cawthorne (2003). The DPPIV
resistant GLP-1 analogue, BIM 51077, improves diabetic control in ZDF rats.
Diabetologia 46, Suppl. 2, A169, Abs. 482.
68.
G. Schmid, V. Converset, N. Walter, M. Sennitt, M. Ward, M. Cawthorne and J.C.
Sanchez (2003). Effect of high fat diet on the expression of proteins in muscle, adipose
tissues and liver of C57Bl/6 mice. Diabetologia 46, Suppl. 2, A207, Abs. 596.
69.
R. Ngala, S. Wang, M.A. Cawthorne and J.R.S. Arch (2003). Atypical pharmacology and
opposing effects of -adrenoceptor agonists on glucose uptake and pyruvate oxidation in
skeletal muscle. Diabetologia 46, Suppl. 2, A210, Abs. 606.
70.
S. Wang, M.A. Cawthorne, J.R.S. Arch and J.C. Clapham (2003). Increased adiposity
and low leptin in transgenic mice overexpressing UCP-3 in skeletal muscle after long
term high fat feeding. Obes. Res. 11(9), Suppl, A30, Abs. 122-OR.
71.
R.A. Ngala; S.J.Y. Wang, M.A. Cawthorne and J.R.S. Arch (2004). Biphasic and atypical
pharmacology of glucose uptake in mouse isolated soleus muscle is dependent on the
β2-adrenoceptor Br. Pharmacol. Soc. Pa2 online Vol 2(1), Abs. 008P
http://www.pa2online.org/abstractindex.html
72.
K. Smith, E. Wargent, A. Morrison, E. Grau, D. Smart, M. Cawthorne and J.Arch (2004).
Normal suppression of feeding by leptin, but enhanced response to CB-1 receptor
antagonists in BRS-3 knockout mice. Int. J. Obes. 28, Suppl. 1, S110, Abs. T3:P3-024.
73.
R.A. Ngala, S. Wang, J. O’Dowd, M.A. Cawthorne and J.R.S. Arch (2004). Atypical
pharmacology and opposing effects of β-adrenoceptor agonists on glucose uptake in
C2C12 cells: similarity with mouse soleus muscle pharmacology. Fundam. Clin.
Pharmacol. 18, Suppl. 1, 36, Abs. P 04.22.
74.
J.R.S Arch, E. Wargent, M.V. Sennitt, C. Stocker, A.E.Mayes, L. Brown, J. O’Dowd, S.
Wang, A.W.C. Einerhand, I. Mohede and M.A. Cawthorne (2005). Prolonged treatment
of genetically obese mice with conjugated linoleic acid (CLA) improves glucose tolerance
and lowers plasma insulin concentration: possible involvement of PPAR activation. Obes.
Rev. 6, Suppl. 1, 43, Abs. T2: O103.
75.
P. Wong-Kai-In, M.A. Cawthorne, E. Wargent and G. Thomas (2005). PSN357, a novel
glycogen phosphorylase inhibitor with anti-hyperglycemic efficacy in rodent models of
diabetes. Diabetes 54, Suppl. 1, A140, Abs. 567-P.
76.
M.C.T. Fyfe, M.A. Cawthorne, M.V. Sennitt and R.L. Printz (2005). Antihyperglycemic
effects of novel long- and short-acting glucokinase activators (PSN105 and PSN010) in
diabetic animals. Diabetes 54, Suppl. 1, A129, Abs. 522-P.
77.
J.F. O’Dowd, C. Cornick, C.J. Stocker, S.J.Y. Wang, M.A. Cawthorne and J.R S. Arch
(2005). Identification of preprodynorphin as a pancreatic gene associated with increased
susceptibility to diabetes. Diabetologia 48, Suppl. 1, A158, Abs. 425.
78.
M. Cawthorne, E. Wargent, J. O’Dowd, D. Hislop, J. Arch and C. Stocker (2005).
Pharmacologic treatment of dams programs offspring to resist diet-induced obesity.
Obes. Res. 13, Suppl 1, A1, 2-OR.
79.
C. Stocker, E. Wargent, K. Smith, J. O’Dowd, J. Arch and M. Cawthorne (2006). Early
life programming of appetite by maternal leptin administration. Obes. Rev. 7, Suppl 2,
153, PO0132.
80.
C. Stocker, E. Wargent, J. O'Dowd, D. Carling, J. Arch and M. Cawthorne (2006).
Leptin supplementation in early life programmes muscle metabolism. Obes. Rev. 7,
Suppl 2, 43, OP0015.
81.
C. Stocker, E. Wargent, J. O'Dowd, R. Ngala, D. Carling, J. Arch and M. Cawthorne
(2007). Patterns of postnatal growth impact on the early life programming of energy
balance. Early Hum. Dev. 83, Suppl 1, S113, Abs P1-109.
82.
M.A. Cawthorne, E. Wargent, M. Zaibi, C. Stott and S. Wright (2007). The CB-1
antagonist delta-9-tetrahydrocannabivarin (THCV) has anti-obesity activity in dietaryinduced obese (DIO) mice. ‘17 Annual Symposium on the Cannabinoids’, Burlington,
Vermont, International Cannabinoid Research Society, page 141.
III. Book Chapters, Conference Proceedings and Specialist Reviews
1.
M.A. Cawthorne (1979). The use of animal models for the detection and evaluation of
compounds for the treatment of obesity. In Animals Models of Obesity, Ed. M.F.W.
Festing. MacMillan Press, London.
2.
M.A. Cawthorne (1981). Is tolerance to anorectic drugs a real phenomenon or an
experimental artefact? In Anorectic agents: mechanism of action and tolerance. Ed.
S. Garattini and R. Samanin pp. 1-17.
3.
M.A. Cawthorne, M.L. Carroll, Alison L. Levy, Carolyn A. Lister, M.V. Sennitt, S.A.
Smith and P. Young (1984). Effects of novel -adrenoceptor agonists on
carbohydrate metabolism: relevance for the treatment of non-insulin dependent
diabetes. Int. J. Obesity, 8, Suppl. 1, 93-102.
4.
M.A. Cawthorne (1987). Lipid metabolism in diabetes. Biochem. Soc. Trans., 15,
343-345.
5.
M.A. Cawthorne, S.A. Smith and P. Young (1987). Effect of thermogenic drugs on
insulin sensitivity and glucose utilization. Recent Adv. Obesity Res., 5, 312-318.
6.
M.A. Cawthorne (1989). Does brown adipose tissue have a role to play in glucose
homeostasis? Proceeding by the Nutrition Soc., 48, 207-214.
7.
S.A. Smith, M.V. Sennitt and M.A. Cawthorne (1990). BRL 35135: an orally active
antihyperglycaemic agent with weight reducing effects. In New Antidiabetic Drugs,
ed. C.J. Bailey and P.R. Flatt. Smith-Gordon. London pp. 177-189.
8.
M.A. Cawthorne (1990). Thermogenic drugs: The potential of selective
-adrenoceptor agonists as anti-obesity drugs. Progress in Obesity Research. Ed Y
Oomura, John Libbey, London pp. 567-574.
9.
J.R.S. Arch, M.A. Cawthorne, K.A. Coney, B.A. Gusterton, V. Piercy, J. Wallace, S.
Wilson (1991). -adrenoceptor mediated control of thermogenesis, body composition
and glucose homeostasis. In "Obesity and Cachexia" Ed. N.J. Rothwell and M.J.
Stock, John Wiley, pp. 241-267.
10.
S.P. Roberts, J. Kelly, M.A. Cawthorne and M.V. Sennitt (1991). The effects of
angiotensin II on post-adrenoceptors in the human isolated saphenous
vein. Adrenoceptors: Structure, Mechanisms, Function. Advances in
Pharmacological Sciences. Ed. Birkhauser Verlag, Basel. pp. 361-362.
11.
M.A. Cawthorne (1992). Thermogenic drugs. In Obesity. Ed. P. Bjorntorp and B.B.
Brodoff. L.B. Lippincott & Co. Philadelphia. pp. 762-77.
12.
M.A. Cawthorne, M.V. Sennit, J.R.S. Arch and S.A. Smith (1992). BRL 35135, a
potent and selective atypical ß-adrenoceptor agonist. Am. J. Clin. Nut., 55,
252S-257S.
13.
M.A. Cawthorne (1999). Thiazolidinediones in the treatment of insulin resistance
syndrome. In Progress in Obesity Research: 8. Ed. B. Guy-Grand and G. Ailhaud.
John Libbey, London. pp. 517-524.
14.
M.A. Cawthorne and M. Heald (2000). Leptin Amgen. In Curr. Opin. Oncol.
Endocrine Metabol. Invest. Drugs 2, 217-226.
15.
M.A. Cawthorne (2005). Promising new targets for the next generation of anti-obesity
drugs. In Solvay Pharmaceutical Conferences ‘Obesity and Metabolic Disorders’.
Ed. J. Antel, N. Finer, D. Heal and G. Krause, IOS Press, Amsterdam, pp201-213.
16.
M.A. Cawthorne. Opportunities and challenges for the development of
pharmacological therapies for obesity treatment. Obes Rev. 2007 Mar;8 Suppl 1:131–
136
2008